Skip to main content
. 2010 Apr 13;102(9):1371–1377. doi: 10.1038/sj.bjc.6605653

Figure 3.

Figure 3

Cumulative incidence of hyperbilirubinemia (⩾1.5 × upper limit of normal [ULN]) by UGT1A1 TA-repeat genotype for pazopanib-treated white patients from both Study 1 and Study 2. The cumulative incidence of total bilirubin (TBL) ⩾1.5 × ULN for each genotype group at a time point (weeks) is the proportion of patients from the group who had at least one on-treatment TBL value of 1.5 × ULN or greater on or before the time point.